Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

WHO Kick-Starts Pilot For Prequalification Of Biologics/Biosimilars

Executive Summary

Manufacturers are being invited to submit expressions of interest in relation to two anticancer monoclonal antibodies on the WHO's essential list of medicines.

You may also be interested in...



WHO Prequalifies Celltrion’s Rituximab

Celltrion's Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the World Health Organization.

WHO Prequalifies First Ever Biosimilar

Samsung Bioepis’ Ontruzant trastuzumab biosimilar has become the first biosimilar to be prequalified by the World Health Organization.

IGBA Makes Access Pact With WHO

The World Health Organization has taken an “important first step” towards increased collaboration with the generics and biosimilars industries through an agreement with the International Generic and Biosimilar Medicines Association to promote access to medicines.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS123446

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel